| abstract |
The present invention describes a method of treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). In certain embodiments, the invention encompasses methods of treatment of CLL and SLL using a BTK inhibitor. In certain embodiments, the invention encompasses methods of treating a subtype of CLL and SLL using a BTK inhibitor, the CLL subtype comprising a patient susceptible to thrombosis and after treatment with a BTK inhibitor Increases the CLL subtype of mononuclear and natural killer (NK) cells in peripheral blood. In certain embodiments, the invention encompasses methods of treatment of CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody. |